Literature DB >> 29778234

EGFL7 and RASSF1 promoter hypermethylation in epithelial ovarian cancer.

Yanisa Rattanapan1, Veerawat Korkiatsakul1, Adcharee Kongruang1, Takol Chareonsirisuthigul2, Budsaba Rerkamnuaychoke1, Anna Wongkularb3, Sarikapan Wilailak3.   

Abstract

DNA methylation is one of the epigenetic mechanisms associated with gene expression and plays a key role as in activation and deactivation of oncogenes and tumor suppressor genes, respectively. This study employed DNA methylation array to identify methylated genes which are highly correlated with various phenotypes of epithelial ovarian cancer (EOC) in Thai patients and to quantify promoter CpG-island methylation of candidate genes. Tissues from patients with serous and non-serous EOC showed significantly higher promoter methylation of EGFL7 and RASSF1 compared to benign cases. These results indicate the potential of investigating promoter CpG-island methylation of cancer-associated genes as biomarkers of disease progression and even possibly of early detection.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bisulfite pyrosequencing; DNA methylation microarray; Epithelial ovarian cancer; Promoter hypermethylation

Mesh:

Substances:

Year:  2018        PMID: 29778234     DOI: 10.1016/j.cancergen.2018.04.117

Source DB:  PubMed          Journal:  Cancer Genet


  2 in total

Review 1.  Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.

Authors:  Alka Singh; Sameer Gupta; Manisha Sachan
Journal:  Front Cell Dev Biol       Date:  2019-09-19

2.  The Polymorphism and Expression of EGFL7 and miR-126 Are Associated With NSCLC Susceptibility.

Authors:  Weipeng Liu; Yunyun Zhang; Fengdan Huang; Qianli Ma; Chuanyin Li; Shuyuan Liu; Yan Liang; Li Shi; Yufeng Yao
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.